11 March 2021
Visiongain has published a new report on Aflatoxicosis Treatment Market Report to 2031: Forecasts by Treatment (Blood Transfusion, Oxygen Therapy, Antibiotics, Antihistamines, Immunosuppressant, and Others) PLUS COVID-19 Recovery Scenarios.
Global Aflatoxicosis Treatment market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.
COVID-19 Impact on Aflatoxicosis Treatment Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the aflatoxicosis treatment market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.
Increasing Instances of Foodborne Illness
Aflatoxins are toxic substances produced by a few types of fungi that are found naturally across the world; they can pollute food crops and stance a severe health risk to people and livestock. According to the World Health Organization (WHO), aflatoxins pose an important economic burden, triggering an estimated to be around 25% or more of the world’s food yields to be ruined annually.
Growing Awareness and Rising Spending in the Research & Development
The key factors pushing the growth of the aflatoxicosis treatment market are the prevalence of aflatoxicosis disease around the world. Besides, increased disposable income in developing countries such as India and China and rising healthcare spending are also accelerating the growth of the aflatoxicosis treatment market. Moreover, rising awareness among the population and the development of healthcare infrastructure are contributing to the target industry growth. Therefore, the rising research & development activities to develop ground-breaking and effective treatments for aflatoxicosis is fueling the target industry growth.
Expansion Opportunities in Emerging Markets
The rising food trade across the boundaries of developing markets rises the opportunity for global aflatoxicosis treatment. The growing occurrences of food-borne diseases and inappropriate hygiene & processing circumstances in the factories. Moreover, growing cases of mycotoxin outbreaks from developing countries such as Asia and Africa are likely to create lucrative opportunities for the target industry growth. These countries are frequently exposed to high levels of aflatoxins, which leads to immunotoxicity, carcinogenicity, and growth retardation in animals.
Key players operating in the global Aflatoxicosis Treatment market are Pfizer Inc., Zydus Cadilla, Glaxo Smith Kline, Sanofi, Johnson and Johnson, Abbott Laboratories, and many others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.